Around the Helix: Cell and Gene Therapy Company Updates – April 24, 2024
Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.
First Patient With Gastric Cancer Dosed in iNKT/CTLA-4 Inhibitor/Anti-PD-L1 Trial
A case study previously described successful immune modulation with AgenT-797 in a patient with high-risk gastric cancer leading to a partial response.
European Commission Approves Janssen and Legend Biotech’s Carvykti for Expanded Indication in Earlier Line Multiple Myeloma
The EC’s decision comes several weeks after the FDA approved cilta-cel for a similar expanded indication.
EGFR-Targeting γδ2T-Cell Cleared for Solid Tumor Trial
Acepodia is also evaluating a CD20-targeted γδ2T-cell therapy in patients with non-Hodgkin lymphoma.
CGTLive®’s Weekly Rewind – April 19, 2024
Review top news and interview highlights from the week ending April 19, 2024.
FDA Requires Boxed Warnings for Secondary Cancer for Approved CAR-T Therapies
The FDA has requested that black box warnings related to secondary cancer risks be added to all 6 CAR-T therapies currently on the market.
